原发进展型多发性硬化患者的疾病修饰治疗与丧失行走功能时间
这项多中心、观察性、回顾性比较效果研究基于意大利多发性硬化登记数据,纳入665例原发进展型多发性硬化(PPMS)患者,经倾向评分匹配后分析409例(治疗288例、未治疗121例)。结果显示,疾病修饰治疗(DMT)暴露与更高的EDSS 7.0分风险相关(aHR 1.75),但DMT与重叠复发的交互项与降低的EDSS 7.0分风险相关(aHR 0.33)。
要点
- 匹配队列中37%(152/409)的患者在中位随访10.6年后达到EDSS 7.0分。
- 基线EDSS更高(aHR 1.32)和重叠复发(aHR 2.37)与EDSS 7.0分风险升高相关。
- DMT暴露与EDSS 7.0分风险升高相关(aHR 1.75),但与重叠复发的交互项与风险降低相关(aHR 0.33)。
核心结论
- 结果表明炎症也发生于PPMS患者,可能参与长期残疾,当前许可的DMT可能通过抑制炎症与降低成为轮椅依赖的风险相关。
研究设计与样本
- 多中心、观察性、回顾性比较效果研究,数据于2018年11月28日从意大利多发性硬化登记中提取,分析时间为2021年6月至12月。
- 共3298例PPMS患者,排除2633例不符合ORATORIO试验入组标准者,余665例(平均[SD]年龄43.0[10.7]岁;女性366例[55.0%])。
- 665例中进一步选取409例进行倾向评分匹配(治疗288例,未治疗121例)。
- 平均研究随访11年。
主要发现
- 匹配队列中,平均(SD)随访10.6(5.6)年期间,37%(152/409)的患者达到EDSS 7.0分。
- 基线EDSS较高与EDSS 7.0分风险升高相关(aHR 1.32;95% CI 1.13-1.55;P < .001)。
- 重叠复发与EDSS 7.0分风险升高相关(aHR 2.37;95% CI 1.24-4.54;P = .009)。
- DMT暴露与EDSS 7.0分风险升高相关(aHR 1.75;95% CI 1.04-2.94;P = .03)。
- DMT与重叠复发的交互项与EDSS 7.0分风险降低相关(aHR 0.33;95% CI 0.16-0.71;P = .004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking. OBJECTIVE: To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, observational, retrospective, comparative effectiveness research study. Data were extracted on November 28, 2018, from the Italian multiple sclerosis register and analyzed from June to December 2021. Mean study follow-up was 11 years. Included in the study cohort were patients with a diagnosis of PPMS and at least 3 years of Expanded Disability Status Scale (EDSS) evaluations and 3 years of follow-up. MAIN OUTCOMES AND MEASURES: The risk of reaching an EDSS score of 7.0 was assessed through multivariable Cox regression models. EXPOSURES: Patients who received DMT before the outcome were considered treated. DMT was assessed as a time-dependent variable and by class of DMT (moderately and highly effective). RESULTS: From a total of 3298 patients with PPMS, 2633 were excluded because they did not meet the entry criteria for the phase 3, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with PPMS (ORATORIO) trial. Among the remaining 665 patients (mean [SD] age, 43.0 [10.7] years; 366 female patients [55.0%]), 409 were further selected for propensity score matching (288 treated and 121 untreated patients). In the matched cohort, during the study follow-up, 37% of patients (152 of 409) reached an EDSS score of 7.0 after a mean (SD) follow-up of 10.6 (5.6) years. A higher EDSS score at baseline (adjusted hazard ratio [aHR], 1.32; 95% CI, 1.13-1.55; P < .001), superimposed relapses (aHR, 2.37; 95% CI, 1.24-4.54; P = .009), and DMT exposure (aHR, 1.75; 95% CI, 1.04-2.94; P = .03) were associated with a higher risk of an EDSS score of 7.0, whereas the interaction term between DMT and superimposed relapses was associated with a reduced risk of EDSS score of 7.0 (aHR, 0.33; 95% CI, 0.16-0.71; P = .004). Similar findings were obtained when treatment according to DMT class was considered and when DMT was included as a time-dependent covariate. These results were confirmed in the subgroup of patients with available magnetic resonance imaging data. CONCLUSIONS AND RELEVANCE: Results of this comparative effectiveness research study suggest that inflammation also occurs in patients with PPMS, may contribute to long-term disability, and may be associated with a reduced risk of becoming wheelchair dependent by current licensed DMTs.
引用
- Portaccio E, Fonderico M, Iaffaldano P, et al. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis. JAMA Neurol. 2022. PMID: 35877104. doi:10.1001/jamaneurol.2022.1929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。